Lisdexamfetamine vs Methylphenidate for focus
Short answer: For focus, users rate them about the same: 87% report improvement with Lisdexamfetamine (200 reports) and 83% with Methylphenidate (262 reports).
Lisdexamfetamine has 58 meta-analyses and 112 randomized trials on PubMed; Methylphenidate has 383 and 1,123.
Based on 439 reports about Lisdexamfetamine and 567 about Methylphenidate. Not medical advice.
| Lisdexamfetamine Medication | Methylphenidate Medication | |
|---|---|---|
| Users say it helped | 41%helped281 reports · high confidence | 39%helped352 reports · high confidence |
| Verdict | Mixed | Mixed |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 58 / 112 | 383 / 1,123 |
| Mainly used for | ||
| Focus % reporting improvement | 87% (200) | 83% (262) |
| Mood % reporting improvement | 50% (82) | 41% (66) |
| Energy % reporting improvement | 61% (62) | 61% (67) |
| Anxiety % reporting improvement | 39% (36) | 29% (48) |
| Sleep % reporting improvement | 12% (17) | 29% (21) |
| Common side effects | anxiety, insomnia, fatigue, irritability | anxiety, jitteriness, insomnia, fatigue |
| Typical dose reported | Not listed | Not listed |
Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
Lancet Psychiatry, 2018 ↗“It's been a game changer for my focus and energy levels, really brought me back to life.”
Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
Lancet Psychiatry, 2018 ↗“I tried both ritalin worked way better in me like way better.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate